XARELTO 20 MG
RIVAROXABAN : 20 MG RIVAROXABAN : 15 MG · DIN 02441535 · BAYER INC
Health Canada status: CANCELLED POST MARKET
What is XARELTO?
XARELTO 20 MG contains RIVAROXABAN : 20 MG RIVAROXABAN : 15 MG. It is listed in the Health Canada Drug Product Database under DIN 02441535, held by BAYER INC, supplied as KIT ; TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 01-Dec-2018. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is XARELTO used for?
Prevention of VTE (THR/TKR); treatment/prevention of DVT and PE; prevention of stroke/systemic embolism in atrial fibrillation; prevention of CV events in CAD with or without PAD (2.5 mg dose).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02441535 |
|---|---|
| Brand name | XARELTO |
| Generic / active ingredient | RIVAROXABAN : 20 MG RIVAROXABAN : 15 MG |
| Manufacturer | BAYER INC |
| Strength | 20 MG |
| Dosage form | KIT ; TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | B01AF01 RIVAROXABAN |
| AHFS class | 20:12.04.14 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 01-Dec-2018 |
| Original market date | 2015-11-02 00:00:00 |
How is it administered?
VTE prevention (THR/TKR): 10 mg OD. VTE treatment: 15 mg BID for 3 weeks, then 20 mg OD. SPAF: 20 mg OD (15 mg if CrCl 30-49 mL/min). CAD/PAD: 2.5 mg BID with ASA 75-100 mg OD.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not specified in the provided text sections (refer to STORAGE AND STABILITY section 45).
How is it supplied?
Not explicitly detailed in provided text summary, though 2.5 mg, 10 mg, 15 mg, and 20 mg strengths are listed.
Contraindications
Active bleeding; lesions/conditions with high bleeding risk; strong dual CYP 3A4/P-gp inhibitors; other anticoagulants; hepatic disease with coagulopathy; pregnancy; nursing; hypersensitivity.
Warnings and precautions
Premature discontinuation increases thrombotic risk. Increased bleeding risk; use caution with neuraxial anesthesia (spinal/epidural hematoma risk). Not recommended for prosthetic heart valves.
What can be used instead?
Other Canadian products sharing ATC code B01AF01 RIVAROXABAN. 68 of 97 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AG-RIVAROXABAN | 10 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02527995 |
| AG-RIVAROXABAN | 15 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02528002 |
| AG-RIVAROXABAN | 2.5 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02555255 |
| AG-RIVAROXABAN | 20 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02528010 |
| APO-RIVAROXABAN | 10 MG | TABLET | APOTEX INC | MARKETED | DIN 02470497 |
| APO-RIVAROXABAN | 15 MG | TABLET | APOTEX INC | MARKETED | DIN 02470500 |
| APO-RIVAROXABAN | 2.5 MG | TABLET | APOTEX INC | MARKETED | DIN 02541734 |
| APO-RIVAROXABAN | 20 MG | TABLET | APOTEX INC | MARKETED | DIN 02470519 |
| AURO-RIVAROXABAN | 10 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02560356 |
| AURO-RIVAROXABAN | 15 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02560364 |
Who else supplies RIVAROXABAN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. RIVAROXABAN appears in 2966 registered pack listings across 14 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.